U
TBPH icon

UBS’s Theravance Biopharma TBPH Stock Holding History

UBS’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$51K Sell
2,177
-7,471
-77% -$217K ﹤0.01% 6800
2014
Q2 		$308K Buy
+9,648
New +$290K ﹤0.01% 4710

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's TBPH Position: Q3 2014 in Review

UBS reduced its Theravance Biopharma (TBPH) stake by 77% in Q3 2014, selling an estimated $217K and leaving 2,177 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #6800.

UBS first reported a position in TBPH in Q2 2014 and has held it in 2 quarters since. The position peaked at $308K in Q2 2014. 92 funds tracked by Wall St. Rank hold TBPH as of Q3 2014.

  • UBS held 2,177 shares of Theravance Biopharma worth $51K as of Q3 2014.
  • UBS sold 7,471 Theravance Biopharma shares in Q3 2014, an estimated $217K.
  • Theravance Biopharma made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6800 holding.
  • UBS first reported a position in Theravance Biopharma in Q2 2014 and has held it in 2 quarters since.
  • UBS's Theravance Biopharma position peaked at $308K in Q2 2014.
  • 92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.